{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T04:04:20Z","timestamp":1780113860566,"version":"3.54.0"},"reference-count":25,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2026,5,30]]},"DOI":"10.1536\/ihj.25-686","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:10:37Z","timestamp":1778883037000},"page":"221-227","source":"Crossref","is-referenced-by-count":0,"title":["Relevant Adverse Events and Drug Discontinuation of Sacubitril\/Valsartan in Patients with Transthyretin Amyloid Cardiomyopathy - Insights from the REVIEW-HF Registry"],"prefix":"10.1536","volume":"67","author":[{"given":"Yukihiro","family":"Watanabe","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School"},{"name":"Division of Cardiovascular Intensive Care, Nippon Medical School Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Kubota","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshige","family":"Murata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Uchiyama","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuniya","family":"Asai","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahito","family":"Nasu","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Iwate Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kitasato University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Kagiyama","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine"},{"name":"Department of Digital Health and Telemedicine, R&amp;D"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kida","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, St. Marianna University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Hyogo Prefectural Awaji Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Osaka General Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Ijichi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokai University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiro","family":"Shibata","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshiro","family":"Kanaoka","sequence":"additional","affiliation":[{"name":"Department of Medical and Health Information Management, National Cerebral and Cardiovascular Center"},{"name":"Department of Cardiovascular Medicine, Nara Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, Toho University Faculty of Medicine"},{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol 2019; 73: 2872-91.","DOI":"10.1016\/j.jacc.2019.04.003"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Nativi-Nicolau J, Siu A, Dispenzieri A, <i>et al<\/i>. Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey. JACC CardioOncol 2021; 3: 537-46.","DOI":"10.1016\/j.jaccao.2021.08.009"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Maurer MS, Schwartz JH, Gundapaneni B, <i>et al<\/i>. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med 2018; 379: 1007-16.","DOI":"10.1056\/NEJMoa1805689"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Maurer MS, Kale P, Fontana M, <i>et al<\/i>. Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis. N Engl J Med 2023; 389: 1553-65.","DOI":"10.1056\/NEJMoa2300757"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Gillmore JD, Judge DP, Cappelli F, <i>et al<\/i>. Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy. N Engl J Med 2024; 390: 132-42.","DOI":"10.1056\/NEJMoa2305434"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Fontana M, Berk JL, Gillmore JD, <i>et al<\/i>. Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. N Engl J Med 2025; 392: 33-44.","DOI":"10.1056\/NEJMe2410890"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Kazi DS, Bellows BK, Baron SJ, <i>et al<\/i>. Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy. Circulation 2020; 141: 1214-24.","DOI":"10.1161\/CIRCULATIONAHA.119.045093"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ioannou A, Massa P, Patel RK, <i>et al<\/i>. Conventional heart failure therapy in cardiac ATTR amyloidosis. Eur Heart J 2023; 44: 2893-907.","DOI":"10.1093\/eurheartj\/ehad347"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Porcari A, Cappelli F, Nitsche C, <i>et al<\/i>. SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy. J Am Coll Cardiol 2024; 83: 2411-22.","DOI":"10.1016\/j.jacc.2024.03.429"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. McMurray JJ, Packer M, Desai AS, <i>et al<\/i>. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993-1004.","DOI":"10.1056\/NEJMoa1409077"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Solomon SD, McMurray JJV, Anand IS, <i>et al<\/i>. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med 2019; 381: 1609-20.","DOI":"10.1056\/NEJMoa1908655"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Matsumoto S, McMurray JJV, Nasu T, <i>et al<\/i>. Relevant adverse events and drug discontinuation of sacubitril\/valsartan in a real-world Japanese cohort: REVIEW-HF registry. J Cardiol 2024; 84: 133-40.","DOI":"10.1016\/j.jjcc.2023.11.005"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Negreira-Caama\u00f1o M, Mart\u00ednez-Del R\u00edo J, Mor\u00f3n-Alguacil A, P\u00e9rez-D\u00edaz P, Piqueras-Flores J. Starting sacubitril-valsartan is safe in patients with transthyretin cardiac amyloidosis and impaired ejection fraction. Rev Port Cardiol 2023; 42: 183-6.","DOI":"10.1016\/j.repc.2022.12.008"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kitaoka H, Izumi C, Izumiya Y, <i>et al<\/i>. JCS 2020 Guideline on Diagnosis and Treatment of Cardiac Amyloidosis. Circ J 2020; 84: 1610-71.","DOI":"10.1253\/circj.CJ-20-0110"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Perugini E, Guidalotti PL, Salvi F, <i>et al<\/i>. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005; 46: 1076-84.","DOI":"10.1016\/j.jacc.2005.05.073"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Castano A, Haq M, Narotsky DL, <i>et al<\/i>. Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis. JAMA Cardiol 2016; 1: 880-9.","DOI":"10.1001\/jamacardio.2016.2839"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Velazquez EJ, Morrow DA, DeVore AD, <i>et al<\/i>. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med 2019; 380: 539-48.","DOI":"10.1056\/NEJMoa1812851"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Mann DL, Givertz MM, Vader JM, <i>et al<\/i>. Effect of Treatment With Sacubitril\/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA Cardiol 2022; 7: 17-25.","DOI":"10.1001\/jamacardio.2021.4567"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kittleson MM, Ruberg FL, Ambardekar AV, <i>et al<\/i>. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2023; 81: 1076-126.","DOI":"10.1016\/j.jacc.2022.11.022"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Garcia-Pavia P, Gonzalez-Lopez E, Anderson LJ, <i>et al<\/i>. Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association. Eur Heart J 2026; 47: 22-36.","DOI":"10.1093\/eurheartj\/ehaf710"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Yan CL, Gallo RA, Vasquez Martinez M, <i>et al<\/i>. Safety and Efficacy of Traditional Heart Failure Therapies in Patients With Cardiac Amyloidosis and Heart Failure. Am J Cardiol 2023; 204: 360-5.","DOI":"10.1016\/j.amjcard.2023.07.140"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Maurer MS, Bokhari S, Damy T, <i>et al<\/i>. Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Circ Heart Fail 2019; 12: e006075.","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Porcari A, Razvi Y, Masi A, <i>et al<\/i>. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy. Eur J Heart Fail 2023; 25: 515-24.","DOI":"10.1002\/ejhf.2776"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Rapezzi C, Aimo A, Barison A, <i>et al<\/i>. Restrictive cardiomyopathy: definition and diagnosis. Eur Heart J 2022; 43: 4679-93.","DOI":"10.1093\/eurheartj\/ehac543"},{"key":"25","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIRCULATIONAHA.120.047293","volume":"142","year":"2020","unstructured":"25. Kittleson MM, Maurer MS, Ambardekar AV, <i>et al<\/i>. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation 2020; 142: e7-22.","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/67\/3\/67_25-686\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T03:30:58Z","timestamp":1780111858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/67\/3\/67_25-686\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.25-686","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"article-number":"25-686"}}